Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 10/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 6/20 | 0.39 |
| ▸ | AXL | P30530 | 7/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4286316 | 1.00 | MERTK (0.41) | MERTKTBXA2RAXLMETTYRO3 | |
| SCHEMBL13705071 | 0.98 | MERTK (0.43) | MERTKTBXA2RAXLMETTYRO3 | |
| SCHEMBL4292600 | 0.98 | MERTK (0.43) | MERTKTBXA2RAXLMETTYRO3 | |
| SCHEMBL4281906 | 0.89 | MERTK (0.42) | MERTKAXLMETTYRO3ADORA2A | |
| SCHEMBL4292612 | 0.89 | MERTK (0.42) | MERTKAXLMETTYRO3ADORA2A | |
| SCHEMBL13705061 | 0.87 | MERTK (0.44) | MERTKAXLMETTYRO3ADORA2A | |
| SCHEMBL4286364 | 0.87 | MERTK (0.44) | MERTKAXLMETTYRO3ADORA2A | |
| SCHEMBL4284063 | 0.80 | CA1 (0.43) | MERTKAXLMETTYRO3 | |
| SCHEMBL4287626 | 0.80 | CA1 (0.38) | KLK7KLK5 | |
| SCHEMBL4294358 | 0.80 | CA1 (0.43) | MERTKAXLMETTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MERTK 1451/4885TBXA2R 1614/4885AXL 1873/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MERTK 1451/4885TBXA2R 1614/4885AXL 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.